Please assess the completion status of the following clinical trial:

Trial Title: Pemetrexed Disodium and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Advanced solid tumor malignancy for which there is no potentially curative treatment; there is no limit to the number of prior lines of therapy~* Performance status Eastern Cooperative Oncology Group (ECOG) equal or less than 1~* Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =\< 3 x upper institutional limit (ULN)~* Total bilirubin =\< 1.5 ULN~* Creatinine clearance (CrCl) \>= 45 mL/min as measured by the standard Cockcroft-Gault equation~* International normalized ratio (INR) =\< 1.5 (if not due to anticoagulants)~* White blood cell count (WBC) \>= 3,000 cells/mm3~* Absolute neutrophil count (ANC) \>= 1,500 cells/mm3~* Platelets \>= 100,000 cells/mm3~* Hemoglobin (Hgb) \>= 8.5 g/dL~* Prior toxicities are allowed as long as they are stable and would not interfere with study drug toxicity assessment~* Measurable or evaluable disease by Response Evaluation Criteria In Solid Tumors (RECIST) (v 1.1)~* Ability to understand and the willingness to sign a written informed consent document; a signed informed consent must be obtained prior to any study specific procedures~* Women of childbearing potential must have a negative pregnancy test performed within 7 days prior to the start of treatment; women of childbearing potential and men must agree to use a medically accepted form of birth control for the duration of study participation; men must agree to use a medically accepted form of birth control for 2 months following completion of study treatment~Exclusion Criteria:~* Any investigational agent within 4 weeks of first dose of study treatment~* Unwillingness or inability to take folic acid, vitamin B12, or dexamethasone~* Known or presumed intolerance of pemetrexed or sorafenib; unable to swallow medication; suspected malabsorption~* Active illicit substance or alcohol abuse~* Contraindication to antiangiogenic agents, including:~* Pulmonary hemorrhage/bleeding event \>= Grade 2 within 4 weeks or less prior to the first dose of study drug~* Any other hemorrhage/bleeding event \>= Grade 3 within 4 weeks or less prior to the first dose of study drug~* Serious non-healing wound, ulcer, or bone fracture~* Thrombolic or embolic events such as a myocardial infarction, cerebrovascular accident including transient ischemic attacks within the past 6 months~* Major cardiac dysfunction, such as uncontrolled angina, congestive heart failure with New York Heart Association (NYHA) class III or higher, ventricular arrhythmias requiring anti-arrhythmic therapy~* Systolic blood pressure \> 160 mmHg or diastolic pressure \> 100 mmHg despite optimal medical management~* Inability to interrupt aspirin or other nonsteroidal anti-inflammatory agents for a 5 day period~* Serious uncontrolled infection \> Common Terminology Criteria for Adverse Events (CTCAE) (v 4) grade 2~* Peripheral motor or sensory neuropathy\>CTCAE (v4) grade 2~* Uncontrolled metastatic brain disease~* Serum B12 or folate levels below the institution's lower limit of normal. Patients may begin B12/folic acid supplementation and can be reconsidered for study once levels meet the eligibility requirements~* Administration of non-steroidal anti-inflammatory drugs (NSAIDs) within 5 days prior to pemetrexed dosing (note: if a candidate routinely takes NSAIDs prior to enrollment, consider transition to alternate non-NSAID for duration of study treatment, if possible).~* Other condition(s) that in the opinion of the investigator might compromise the objectives of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (enzyme inhibitor therapy, antiangiogenesis) (Type: EXPERIMENTAL): Patients receive pemetrexed disodium IV on day 1 every 2 weeks and sorafenib tosylate PO BID for 4 weeks on days 1-5. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).